Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in patients with relapsed or refractory hematologic malignancies, yet clinical responses remain heterogeneous. Increasing evidence suggests that part of this variability may already be reflected before manufacturing, at the level of the leukapheresis starting material. This review highlights pre-apheresis T-cell fitness as an important upstream biological framework linking patient background to the quality of the starting material, manufacturing performance, and clinical efficacy. Available data indicate that the most informative attributes of high-quality starting material are defined not by T-cell number alone but by the preservation of early-differentiated T-cell subsets, maintenance of functional reserve, resilience to exhaustion-associated dysfunction, and metabolic adaptability. We discuss how prior treatment exposures, including chemotherapy, radiotherapy, and selected targeted agents, can influence these properties according to exposure type, dose intensity, treatment phase, and timing relative to leukapheresis. We further examine how host-related conditions, including immunosenescence, chronic infection, nutritional and metabolic imbalance, and high tumor burden, may alter precursor availability, reshape differentiation architecture, and impair T-cell functional competence before collection. Collectively, these observations support a shift from a quantitative view of leukapheresis products toward a biologically informed assessment of T-cell quality. Defining a favorable pre-collection window and establishing standardized pre-apheresis assessment strategies may therefore facilitate biologically informed leukapheresis planning and future optimization of CAR-T manufacturing and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Chun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: